Literature DB >> 8653895

Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies.

J W Eastman1, R Wong, C L Liao, D R Morales.   

Abstract

Automated HPLC is used to test dried blood-spot specimens from newborns for hemoglobins (Hb) F, A, S, C, E, and D. We present the method and report on its performance determined during >4 years of testing 2.5 x 10(6) newborns. The method features automated derivation of presumptive phenotypes; quantitative quality control and proficiency testing; throughput of one specimen per minute; small sample volume; hemoglobin concentrations quantified with an interlaboratory CV of 14-18%; retention times with interlaboratory CV of <2% and matching, within +/- 0.03 min, of laboratories and reagent lots; control of peak resolution; 0.5% detection limit for Hb S and C, and 1.0% for Hb F, A, E, and D; few interferences; and negligible background and carryover. Shortcomings of the method are the absence of microplate barcode identification and the need for manually pipetting the sample eluate into the microplate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653895

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

1.  Costing model for neonatal screening and diagnosis of haemoglobinopathies.

Authors:  E K Cronin; C Normand; J S Henthorn; M Hickman; S C Davies
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

2.  Neonatal screening of sickle cell anemia: a preliminary report.

Authors:  Sumanta Panigrahi; Predeep Kumar Patra; Prafulla Kumar Khodiar
Journal:  Indian J Pediatr       Date:  2012-01-26       Impact factor: 1.967

3.  Utility of family studies in diagnosing abnormal hemoglobins/thalassemic states.

Authors:  Aruna Rangan; A Handoo; S Sinha; R Saxena; I C Verma; S Kumar; S K Sood; M Bhargava
Journal:  Indian J Pediatr       Date:  2009-04-23       Impact factor: 1.967

4.  Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany.

Authors:  Stephan Lobitz; Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein
Journal:  Eur J Hum Genet       Date:  2014-01-08       Impact factor: 4.246

5.  Hb S/β+-thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the β locus control region.

Authors:  Ali Amid; Melina Cheong; Barry Eng; Meredith Hanna; Betty-Ann Hohenadel; Lisa M Nakamura; Lynda Walker; Isaac Odame; Melanie Kirby-Allen; John S Waye
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  HPLC in characterization of hemoglobin profile in thalassemia syndromes and hemoglobinopathies: a clinicohematological correlation.

Authors:  Rachna Khera; Tejinder Singh; Nita Khuana; Naresh Gupta; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2014-06-05       Impact factor: 0.900

7.  Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells.

Authors:  Sylvia T Singer; Elliott P Vichinsky; Sandra Larkin; Nancy Olivieri; Nancy Sweeters; Frans A Kuypers
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

8.  Newborn screening for sickle cell disease: A 1988-2003 Quebec experience.

Authors:  Nancy Robitaille; Edgard E Delvin; Heather A Hume
Journal:  Paediatr Child Health       Date:  2006-04       Impact factor: 2.253

9.  Newborn screening for hemoglobinopathies in California.

Authors:  Jennifer Michlitsch; Mahin Azimi; Carolyn Hoppe; Mark C Walters; Bertram Lubin; Fred Lorey; Elliott Vichinsky
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

10.  Sickle cell disease in areas of immigration of high-risk populations: a low cost and reproducible method of screening in northern Italy.

Authors:  Donatella Venturelli; Mariachiara Lodi; Giovanni Palazzi; Giuliano Bergonzini; Giada Doretto; Annalisa Zini; Cellini Monica; M Carmen Cano; Mariotti Ilaria; Giuliano Montagnani; Paolo Paolucci
Journal:  Blood Transfus       Date:  2014-03-19       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.